Mr. Haack has over 20 years of experience in life sciences. He started his career at Genentech where he led the Sales Operations team and the successful launch of Rituxan and Herceptin. He was an early employee at Genomic Health where he helped lead and was instrumental in the success of the launch and commercial success of all three Oncotype DX products. Mr. Haack holds an MA degree in Economics and Econometrics.

Dr. Sinha holds the position of adjunct Professor of Biochemistry and Molecular Biology at the Tulane University School of Medicine in New Orleans. Dr. Sinha has over 36 years of experience in biochemical research, Cancer Biomarkers research, and human DNA genotyping and assay commercialization. Previously, Dr. Sihha founded InnoGenomics and ReliaGene Technologies.

Dr. Hall’s career started at Genentech where he was on the medical affairs team that launched Rituxan and Herceptin. At Genomic Health, Dr. Hall formed and led the medical science liaison team and was involved with the launch of the Breast, Colon and Prostate assays. Dr. Hall was the Executive Director of Medical Affairs at Castle Biosciences. He has more than 20 years of industry experience.

Dr. Knopf is an Oncologist with 20 years of academic and industry. He is currently Division Chief of Hematology/Oncology at Alameda Health System and isAssistant Clinical Professor at the UCSF. He is recognized for his expertise and publications in Oncology with a focus on Health Econ. Dr Knopf has a ScB in mechanical engineering from MIT, an MD from UCSF, and an MPH from Johns Hopkins. He trained at Sloan Kettering Cancer Center and the NCI.